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Background/Aims  :  N-terminal  pro-B-type  natriuretic  peptide  (NT-proBNP)  has  recently  been  introduced  as  a  useful 
marker  in  diagnosing  underlying  disease  in  patients  with  dyspnea  and  for  determining  the  prognosis  of  patients  with 
heart  failure.  The  purpose  of  this  study  was  to  evaluate  the  value  of  the  NT-proBNP  as  a  marker  of  disease  severity 
in  patients  with  pericardial  effusions.
Methods :  We  enrolled  69  consecutive  patients  who  showed  moderate  or  large  pericardial  effusion  with  preserved 
left ventricular (LV) systolic function; 42 patients finally participated in the study, and 13 (31.0%) of them showed cardiac 
tamponade. We analyzed the etiologies, the clinical and echocardiographic variables, and the serum NT-proBNP levels 
i n  t h e s e  p a t i e n t s .
Results : The mean NT-proBNP level was 751±1002 ng/L (range 5 to 5289),  and the median level was 385 ng/L 
(interquartile  range  152  to  844).  The  NT-proBNP  levels  were  higher  in  those  patients  with  jugular  venous  distension 
(p=0.002), pulsus paradoxus (p=0.016), heart rate ≥100/min (p=0.006), cardiac tamponade (p=0.001), large pericardial 
effusion (p=0.029), exaggerated respiratory variation of the transmitral inflow (p=0.006), or plethora of the inferior vena 
cava (p=0.01). The NT-proBNP levels showed significant correlation with heart rate (r=0.517, p<0.001) and the diameter 
of  the  inferior  vena  cava  (r=0.329,  p=0.03).
Conclusions : NT-proBNP may be useful as a marker of disease severity in patients suffering from pericardial effusion, 
but  further  prospective  studies  with  more  patients  will  be  needed.
Key  Words  :  Pericardial  effusion;  Natriuretic  peptide;  Brain;  Cardiac  tamponade;  Echocardiography
∙Received  :  August  30,  2007
∙Accepted  :  February  14,  2008
∙Correspondence to : Sang-Gon  Lee,  M.D.,  Cardiovascular  Center,  Division  of  Cardiology,  Department  of  Internal  Medicine,  Ulsan  University  Hospital, 
290-3  Jeonha-Dong,  Dong-Gu,  Ulsan,  682-714,  Korea    Tel  :  82-52-250-7029,  Fax  :  82-52-251-8235
E-mail  :  sglee@uuh.ulsan.kr
INTRODUCTION
Pericardial  effusion  produces  a  continuum  of  pressure 
increases  in  the  pericardium  and  therefore  leads  to  a  wide 
spectrum  of  hemodynamic  and  clinical  manifestations
1).  The 
actual  effect  of  accumulating  pericardial  fluid  on  raising  the 
intrapericardial  pressure  is  determined  by  both  the  rate  of  fluid 
accumulation  relative  to  pericardial  stretch  and  by  the 
effectiveness  of  compensatory  mechanisms
2).  Accordingly,  once 
the  total  intrapericardial  volume  has  caused  the  pericardium  to 
reach  the  noncompliant  region  of  its  pressure-volume  relation, 
critical  tamponade  can  rapidly  develop
3).
To establish the severity of disease in patients with pericardial 
effusion,  especially  in  those  suffering  from  cardiac  tamponade, 
physicians  need  to  consider  the  symptomatic  manifestations, 
physical  examination  signs,  echocardiographic  features,  and 
hemodynamic  characteristics.  This  process  is  complex  and 
difficult,  and  a  simple  diagnostic  supplement,  such  as  a 
biomarker,  is  helpful.
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hormone that is primarily released from the cardiac ventricles. It 
is  synthesized  as  an  inactive  108-amino  acid  pro-hormone 
pro-BNP,  which  is  split  into  the  active  hormone  BNP  and  the 
inactive  N-terminal  fragment  (NT-proBNP),  a  76-amino  acid 
peptide.  Cardiac  myocytes  constitute  the  major  source  of 
BNP-related  peptides,  and  the  main  stimulus  for  synthesis  and 
secretion  is  myocyte  stretch.  BNP  has  a  number  of  systemic 
effects,  including  diuresis,  vasodilatation,  and  inhibition  of  the 
renin-angiotensin-aldosterone  system  and  the  sympathetic 
nervous  system
4, 5).  The  rapid  bedside  assay  for  BNP  and 
N T - p r o B N P  h a s  p r e v i o u s l y  b e e n  s h o w n  t o  b e  u s e f u l  f o r  r u l i n g  
out  heart  failure
6).  The  test  is  also  useful  for  making  the 
diagnosis  of  systolic
7)  or  diastolic  heart  failure
8).  BNP  and 
NT-proBNP  are  predictors  of  cardiovascular  morbidity  and 
mortality  in  patients  suffering  from  stable  coronary  heart 
disease
9),  acute  coronary  syndrome
10),  or  heart  failure
11).
However,  for  patients  with  pericardial  effusions,  the  role  of 
natriuretic peptides as markers for disease severity, progression, 
or  prognosis  is  unknown.  Therefore,  we  undertook  the  present 
study  to  evaluate  the  hypothesis  that  NT-proBNP  could  be  a 
useful  marker  for  assessing  disease  severity  in  patients  with 
pericardial  effusions.
MATERIALS AND METHODS
Subjects
Between  October  2004  and  September  2006,  we  pro-
spectively  enrolled  69  consecutive  patients  with  new  onset 
moderate or large pericardial effusions and preserved LV function 
(ejection fraction ≥45%) on echocardiography, all of whom were 
admitted  to  our  hospital.  Moderate  pericardial  effusion  was 
considered  to  be  present  when  the  anterior  plus  posterior 
echo-free  spaces  were  1  to  2  cm,  and  large  effusion  was 
considered when this figure was more than 2 cm. Patients with 
postoperative  pericardial  effusions,  serum  creatinine  level  more 
than  1.5  mg/dL,  LV  ejection  fraction  less  than  45%,  known 
coronary  or  valvular  heart  disease,  atrial  fibrillation,  or  severe 
circulatory  congestion  were  excluded.  Hence,  43  patients  were 
finally  selected  for  study  participation.  All  patients  underwent 
e c h o c a r d i o g r a p h i c  a n d  D o p p l e r  e x a m i n a t i o n s ,  a n d  b l o o d  
samples  for  determining  the  serum  creatinine  and  NT-proBNP 
levels  were  collected  on  the  same  day.
Clinical  Data
Age,  gender,  weight,  height,  body  mass  index,  NYHA 
classification,  blood  pressure,  presence  or  absence  of  pulsus 
paradoxus  (a  reduction  in  systolic  blood  pressure  greater  than 
10  mmHg  during  inspiration),  heart  rate,  respiratory  rate,  and 
electrocardiographic  findings  were  all  recorded.  Characteristic 
clinical  findings
2)  (dyspnea,  pulsus  paradoxus,  jugular  venous 
distension, tachycardia and hypotension) were also recorded. In 
our study, “overt clinical tamponade” was considered present 
when  heart  rate  was  ≥100/min,  and  there  was  documented 
evidence of systolic blood pressure less than 90 mmHg. Cardiac 
tamponade  was  confirmed  by  two-  dimensional  (2D)  and 
Doppler  echocardiographic  findings;  this  “echocardiographic 
tamponade” was defined as right atrial (RA) or right ventricular 
(RV) collapse, inferior vena cava (IVC) plethora without inspiratory 
collapse,  and  exaggerated  respiratory  variation  of  mitral  early 
filling  velocity. 
Etiologic  investigation  was  done  according  to  the  following 
protocol  suggested  by  Sagrista-Sauleda  et  al.
12) T h e  i n i t i a l  
evaluation  included  basic  laboratory  studies,  chest  radiograph, 
physical  examination,  echocardiography,  evaluation  for  tuber-
culosis,  measurement  of  serum  antinuclear  antibodies  and 
thyroid  hormones,  and  other  investigations  that  were  warranted 
by  the  individual  clinical  findings.  Advanced  evaluation  included 
pericardiocentesis  for  those  patients  with  cardiac  tamponade,  a 
suspicion  of  purulent  pericarditis,  or  a  chronic  large  pericardial 
effusion.  In  addition  to  routine  cytological  and  biochemical 
studies of the pericardial fluid, adenosine deaminase activity was 
measured,  and  the  results  of  polymerase  chain  reaction  (PCR) 
for  tubercle  bacilli  were  recorded.  Subxiphoid  pericardial  biopsy 
with  histologic  examination  and  culture  of  the  biopsy  specimen 
w e r e  n o t  r o u t i n e l y  p e r f o r m e d  i n  t h i s  s t u d y .
Echocardiographic  Study
All  echocardiographic  studies  were  carried  out  using  a 
standard  protocol  on  a  commercially  available  system  (Vivid  7, 
GE  Medical  Systems,  Horten,  Norway).  Echocardiograms  were 
stored digitally and analyzed offline by two cardiologists who had 
no  knowledge  of  the  NT-proBNP  data.  M-mode,  2D,  and 
Doppler recordings were carried out in all patients whose clinical 
status  did  not  make  the  measurements  impossible.  All 
measurements  were  recorded  through  the  whole  respiratory 
cycle and averaged over five cardiac cycles. The dimensions of 
the  cardiac  walls  and  chambers  were  measured  according  to 
the  American  Society  of  Echocardiography  guidelines
13).  The 
interventricular  septal  thickness  (IVST)  at  end  diastole,  LV 
posterior  wall  thickness  (PWT)  at  end  diastole,  and  LV  internal 
dimension  at  end  diastole  and  end  systole  (LVIDd  and  LVIDs, 
respectively) were measured via 2D echocardiographically guided 
M-mode  examination.  The  left  atrial  (LA)  volume  was  measured 
by  the  length-diameter  prolate  ellipsoid  method  at  end  systole. 
On Doppler echocardiographic examination, the transmitral early 
filling velocity (E), late filling velocity (A), deceleration time (DT) of 
E  flow,  E/A  ratio,  early  velocity  of  the  septal  annulus  (E'),  and 
E/E'  were  also  measured.  For  estimating  RV  systolic  pressures 
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Characteristic Value
Men  (n,  %)
Age  (yrs)
Height  (cm)
Body  weight  (kg)
Body  mass  index  (kg/m
2)
NYHA  class  I/II  (n,  %)
NYHA  class  III/IV  (n,  %)
Systolic  blood  pressure  (mmHg)
Diastolic  blood  pressure  (mmHg)
Heart  rate  (min‐1)
NT-proBNP  (ng/L)
‡
Serum  creatinine  (mg/dL)
Etiology  of  effusion  (n,  %)
  M a l i g n a n c y
    Idiopathic
    Tuberculosis
    Hypothyroidism
    Rupture  of  an  ulcerated  aortic  aneurysm
    Connective  tissue  disease
  P u r u l e n t  p e r i c a r d i t i s
Amount  of  pericardial  effusion  (n,  %)
  M o d e r a t e
  L a r g e
Hemodynamic  status  (n,  %)
    Overt  clinical  tamponade
    Echocardiographic  tamponade
    No  tamponade  physiology
18  (42.9%)
57.4±17.6  (15-90)
*
161.6±8.2  (145-178)
56.7±10.2  (35-82)
21.7±3.0  (16.2-28.5)
23  (54.8%)
19  (45.2%)
110  (98-122)
72.9±10.4  (54-96)
92.0±23.4  (54-154)
385  (152-844)
0.96±0.21  (0.61-1.45)
15  (35.7%)
11  (26.2%)
9  (21.4%)
4  (9.5%)
1  (2.4%)
1  (2.4%)
1  (2.4%)
23  (54.8%)
19  (45.2%)
5  (19%)
13  (31%)
29  (69%)
*D a t a  a r e  e x p r e s s e d  a s  m e a n s ± s t a n d a r d  d e v i a t i o n s  ( r a n g e )  f o r  
normally  distributed  variables  or  as  medians  and  interquartile 
ranges  for  asymmetrically  distributed  variables. 
‡N T - p r o B N P ,  N - t e r m i n a l  p r o - B - t y p e  n a t r i u r e t i c  p e p t i d e .
Table  1.  Baseline  characteristics  of  study  subjects  (n=42)
regurgitant jet (TRVmax) and obtained RV systolic pressures by the 
following  equation:
RV  systolic  pressure  =  4(TRVmax)
2 +  R A  p r e s s u r e
RA  pressure  was  estimated  based  on  evaluation  of  IVC 
diameter during respiration. If IVC diameter was small (<1.5 cm) 
and  collapsed  by  at  least  50%  with  respiration,  then  estimated 
RA pressure was 5 mmHg. If IVC diameter was normal (1.5-2.5 
cm),  estimated  RA  pressure  was  10  mmHg  or  15  mmHg 
according to the presence or the absence of IVC collapse with 
respiration,  respectively.  If  the  IVC  was  dilated  (>2.5  cm),  then 
estimated  RA  pressure  was  20  mmHg.
Morphologic features suggestive of tamponade physiology, as 
confirmed  by  2D  echocardiography,  included  RA  compression 
during  late  diastole
14),  RV  collapse  during  early  diastole
15),  and 
IVC  plethora  with  a  lack  of  inspiratory  collapse
16).  Doppler 
hemodynamic  findings  suggestive  of  tamponade  physiology 
included  exaggerated  respiratory  variation  (difference  >25%)  of 
t h e  m i t r a l  E  v e l o c i t y  d u r i n g  i n s p i r a t i o n  a n d  e x p i r a t i o n
17, 18), 
accompanied  by  an  increase  in  hepatic  venous  diastolic  flow 
reversal  on  expiration
18).
Measurement  of  Serum  NT-proBNP  Levels
Peripheral venous blood samples were carefully obtained from 
the antecubital vein and then transferred into standard sampling 
tubes.  NT-proBNP  was  measured  by  employing  the  electro-
chemiluminescence  principle  (Elecsys
Ⓡ  2010/Molecular  analytic 
E710,  Roche  Diagnostics,  Indianapolis,  Ind.,  USA)  using 
sandwich  immunoassay  with  two  polyclonal  antibodies.
Statistical  analysis
SPSS  Inc.  for  Windows Standard  version 12.0 was used for 
statistical  analysis.  The  data  are  expressed  as  means±SDs 
(range) for the normally distributed variables or as medians and 
interquartile  ranges  for  the  asymmetrically  distributed  variables. 
The  quantitative  normally  distributed  data  was  compared  using 
the  Student's  t-test.  The  chi-square  test  was  used  for  non- 
continuous  variables.  Pearson's  correlation  coefficient  was  used 
to  assess  correlations  between  the  NT-proBNP  levels  and  the 
normally  distributed  clinical  and  echocardiographic  variables. 
Natural logarithmic transformation (ln) was used to adjust for the 
asymmetrically  distributed  variables,  including  the  NT-proBNP 
levels. Multivariate regression analysis was performed to establish 
the  independent  clinical  and  echocardiographic  variables  that 
determined  serum  NT-proBNP  levels.  Logistic  regression  was 
performed to assess whether NT-proBNP would add diagnostic 
information  over  clinical  parameters.  A  p  value  of  <  0.05  was 
considered  statistically  significant.
RESULTS
Baseline  patient  characteristics
The baseline clinical and echocardiographic characteristics are 
listed in Table 1. In 11 (26.2%) of 42 patients, the etiology of the 
pericardial  effusion  was  unknown.  The  three  most  frequent 
identifiable causes were: malignancy in 15 (35.7%), tuberculosis 
in  9  (21.4%),  and  hypothyroidism  in  4  (9.5%).  Three  (7.2%) 
patients had other unusual causes: rupture of an ulcerated aortic 
aneurysm,  connective  tissue  disease,  and  purulent  pericarditis 
complicated by mediastinal empyema, respectively. Effusion was 
moderat e i n 23 pat i ent s  and l arge i n 19 pat i ent s.  On t he basi s 
of  clinical  and  echocardiographic  findings,  5  patient  had  overt 
clinical  tamponade  (19%),  13  patients  (31.0%)  had  echocardio-
graphic  cardiac  tamponade,  and  29  (69.0%)  patients  had  no 
tamponade  physiology  (Table  2).  All  patients  with  cardiac 
tamponade  underwent  pericardiocentesis  and  exhibited 
subsequent  clinical  and  hemodynamic  improvement.  Diagnostic 
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With  tamponade 
(n=13)
Without  tamponade
(n=29)
Men  (n,  %)
Age  (yrs)
Height  (cm)
Body  weight  (kg)
Body  mass  index  (kg/m
2)
NYHA  class  I/II  (n,  %)
NYHA  class  III/IV  (n,  %)
Systolic  blood  pressure  (mmHg)
Diastolic  blood  pressure  (mmHg)
Heart  rate  (mim
-1)
NT-proBNP  (ng/L)
Serum  creatinine  (mg/dL)
Jugular  venous  distension  (n,  %)
Pulsus  paradoxus  (n,  %)
LV
¶ e n d - d i a s t o l i c  d i m e n s i o n  ( m m )
LV
¶  end-systolic  dimension  (mm)
IVSTd
¶  (mm)
PWTd
¶  (mm)
Ejection  fraction  (%)
Left  atrial  volume  index  (mL/m
2)
E  (cm/sec)
A  (cm/sec)
E/A  ratio
E’  (cm/sec)
E/E’  ratio
RA
¶ o r  R V
¶  diastolic  collapse  (n,  %)
Exaggerated  respiratory  variation  of  mitral  E  velocity  (n,  %)
Hepatic  venous  diastolic  flow  reversal  during  expiration  (n,  %)
Diameter  of  inferior  vena  cava  (mm)
Plethora  of  inferior  vena  cava  (n,  %)
Estimated  RV
¶ s y s t o l i c  p r e s s u r e  ( m m H g )
5  (38.5%)
56.6±12.5  (30-75)
*
162.5±6.5  (155-173)
56.8±8.0  (45-68)
21.5±2.7  (17.3-25.9)
3  (23.1%)
†
10  (76.9%)
†
102.3±12.0  (85-125)
†
66.9±10.0  (54-86)
‡
116.4±17.1  (88-154)
§
843.9  (665-1896)
†
0.89±0.20  (0.01-1.35)
13  (100%)
§
12  (92.3%)
§
38.5±6.4  (26-50)
†
26.7±5.6  (14-35)
10.1±2.1  (6-13)
10.2±2.0  (7-13)
61.4±7.0  (48-78)
12.5±5.2  (5.3-22.3)
‡
59.0±18.6  (38-100)
66.0±18.4  (38-95)
0.94±0.037  (0.5-1.6)
4.4±1.2  (2-6)§
14.4±5.2  (7-22)
‡
11  (84.6%)
§
13  (100%)
§
10  (76.9%)
†
21.3±5.8  (10-32)
‡
12  (92.3%)
†
35.6±3.3  (31-40)
13  (44.8%)
57.8±19.6  (15-90)
161.3±9.0  (145-178)
56.7±11.2  (35-82)
21.7±3.2  (16.2-28.5)
20  (69.0%)
†
9  (31.0%)
†
119.6±17.7  (95-175)
†
75.6±9.6  (60-96)
‡
81.2±16.6  (54-120)
§
278.4  (53-549)
†
0.99±0.21  (0.70-1.45)
5  (17.2%)
§
4  (13.8%)
§
44.2±5.7  (32-54)
†
27.4±5.0  (17-36)
10.6±1.8  (7-15)
10.4±1.8  (7-15)
63.8±7.8  (45-75)
20.3±10.8  (6.7-50.0)
‡
63.2±18.6  (35-101)
72.3±22.7  (32-125)
1.1±0.6  (0.3-3.7)
6.8±2.3  (3-13)
§
9.9±3.4  (5-19)
‡
3  (10.3%)
§
4  (13.8%)
§
7  (24.1%)
†
17.6±5.2  (9-27)
‡
13  (44.8%)†
33.1±6.4  (22-44)
*D a t a  a r e  e x p r e s s e d  a s  m e a n s ± s t a n d a r d  d e v i a t i o n s  ( r a n g e )  f o r  n o r mally  distributed  variables  or  as  medians  and  interquartile  ranges 
for  asymmetrically  distributed  variables. 
†p<0.01, 
‡p<0.05, 
§p<0.001
¶IVSTd,  interventricular  septal  thickness  at  end‐diastole;  LV,  left  ventricle;  NT-proBNP,  N-terminal  pro-B-type  natriuretic  peptide;  PWTd, 
posterior  wall  thickness  at  end‐diastole;  RA,  right  atrium;  RV,  right  ventricle.
Table  2.  Clinical  and  echocardiographic  characteristics  of  patients  with  tamponade  and  without  tamponade
without  cardiac  tamponade.  NYHA  class  III/IV,  jugular  venous 
distension,  pulsus  paradoxus,  RA  or  RV  collapse,  exaggerated 
respiratory variation of mitral E velocity, hepatic venous diastolic 
f l o w  r e v e r s a l  d u r i n g  e x p i r a t i o n ,  a n d  I V C  p l e t h o r a  w e r e  a l l  m o r e  
common  in  patients  with  cardiac  tamponade  (Table  2).  In 
patients  with  cardiac  tamponade,  the  values  of  systolic  and 
diastolic blood pressure, LV end-diastolic dimension, LA volume 
index,  and  E'  velocity  were  lower  than  in  patients  without 
tamponade;  however,  the  values  of  heart  rate,  NT-proBNP 
levels,  E/E'  ratio,  and  IVC  diameter  were  higher  (Table  2). 
Relationship  between  NT-proBNP  and  clinical  features
The  mean  ln  NT-proBNP  level  was  2.6±0.59  ng/L  (mean 
751±1002  [range  5  to  5,289],  median  385  [interquartile  range 
152  to  844]).  Higher  ln  NT-proBNP  levels  were  observed  in 
those  patients  with  jugular  venous  distension  (2.9±0.50  vs 
2.3±0.54  ng/L,  respectively,  p=0.002),  and  in  those  patients 
with  pulsus  paradoxus  (2.8±0.41  vs  2.4±0.62  ng/L, 
respectively,  p=0.016)  (Figures  1B  and  1C).  The  ln  NT-proBNP 
levels  were  higher  in  patients  with  heart  rates  ≥100/min, 
compared  to  those  patients  with  heart  rates  <100/min 
(2.9±0.42 vs 2.4±0.59 ng/L, respectively, p=0.006) (Figure 1A). 
F u r t h e r m o r e ,  h i g h e r  l n  N T - p r o B N P  l e v e l s  w e r e  o b s e r v e d  i n  
patients  with  cardiac  tamponade  than  in  patients  without  this 
finding  (3.0±0.34  vs  2.4±0.58  ng/L,  respectively,  p=0.001) 
(Figure  1D).  NYHA  class  III  or  IV  patients  showed  a  trend  of 
elevated ln NT-proBNP levels compared with NYHA class I or II 
patients, but this was not statistically significant (2.7±0.51 vs 2.4 
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Figure 1. Distribution of ln NT‐proBNP in patients with pericardial effusion, according to heart rate (A) and presence or absence of jugular 
venous  distension,  pulsus  paradoxus,  and  cardiac  tamponade  (B,  C  and  D).  The  plots  display  the  median,  and  25
th a n d  7 5
th  percentiles 
( l o w e r  a n d  u p p e r  l i m i t s  o f  t h e  b o x e s ) ,  a l o n g  w i t h  e r r o r  b a r s .  J VD,  jugular  venous  distension;  PP,  pulsus  paradoxus;  Tamp,  cardiac 
tamponade.
Figure  2.  C o r re l a t i o n  b e t w e e n  l n  N T - p ro B N P  l e v e l  a n d  h e a rt  r a t e  (A ),  a n d  b e t w e e n  l n  N T - p ro B N P  l e v e l  a n d  I V C  d i a m e t e r (B ).
A
C
A
B
D
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Figure  3.  Receiver-operating  characteristic  curve  analysis  of  ln 
NT-proBNP  level,  according  to  cardiac  tamponade.  Area  under  the 
curve  was  0.83  (95%  confidence  interval  [CI]  0.70-0.96),  and  optimal 
cut‐off value for prediction of the presence of cardiac tamponade was 
436  ng/L.
Figure 4.  Model chi-square  test demonstrating the  increased  diagnostic 
value  of  NT-proBNP  when  combined  with  clinical  parameters  for  the 
diagnosis  of  cardiac  tamponade.  Clinical  parameters  include  systolic 
blood  pressure  and  heart  rate.
p=0.074).  There  was  positive  correlation  between  ln 
NT-proBNP  level  and  heart  rate  (r=0.517,  p<0. 001)  ( Fi gu r e  2A ) .  
There  was  no  relation  between  ln  NT-proBNP  level  and  either 
age,  gender,  or  systolic  or  diastolic  blood  pressure.
Relationship  between  NT-proBNP  and  echocardiographic 
findings
Higher NT-proBNP levels were observed in patients with large 
pericardial  effusions  than  in  patients  with  moderate  pericardial 
effusions  (2.8±0.47  vs  2.4±0.61  ng/L,  respectively,  p=0.029). 
T h e  l n  N T - p r o B N P  l e v e l s  w e r e  h i g h e r  i n  p a t i e n t s  w i t h  
exaggerated  respiratory  variation  of  the  transmitral  inflow, 
compared  to  patients  without  this  finding  (2.9±0.40  vs 
2.4±0.61 ng/L, respectively, p=0.006). The ln NT-proBNP levels 
were  higher  in  patients  with  IVC  plethora,  as  compared  to 
p a t i e n t s  w i t h o u t  t h i s  f i n d i n g  ( 2 . 7 ± 0 . 5 1  v s  2 . 3 ± 0 . 6 0  n g / L ,  
respectively,  p=0.01).  The  ln  NT-proBNP  levels  were  not 
significantly  different  between  patients  with  an  E/E'  ratio  ≥10 
and  patients  with  an  E/E'  ratio  <  10.  There  was  a  positive 
correlation  between  the  ln  NT-proBNP  level  and  IVC  diameter 
(r=0.329,  p=0.03)  (Figure  2B).  There  was  no  significant 
correlation between the ln NT-proBNP level and either LV cavity 
dimensions,  LV  wall  thickness,  LA  volume  index,  E  velocity,  A 
velocity,  E/A  ratio,  E',  E/E'  ratio,  or  estimated  RV  systolic 
pressure.
Multivariable  analysis
For multivariable analysis, we selected variables such as age, 
body  mass  index,  systolic  blood  pressure,  heart  rate,  end- 
diastolic dimension of LV, ejection fraction, LA volume index, E', 
E/E'  ratio,  and  IVC  diameter.  On  multivariable  analysis,  the  ln 
NT-proBNP  level  was  only  independently  related  to  heart  rate 
(p=0.04),  with  an  overall  r
2=0.40.
Increased  NT-proBNP  as  a  diagnostic  marker  of  cardiac 
tamponade
The  receiver  operating  characteristic  (ROC)  analysis  for  NT- 
proBNP  as  a  diagnostic  marker  of  cardiac  tamponade  showed 
that the area under the curve was 0.83 (95% confidence interval 
0.70-0.96)  (p=0.001).  A  cut-off  NT-proBNP  value  of  436  ng/L 
had a specificity of 76% and a sensitivity of 92% in diagnosing 
cardiac  tamponade  (Figure  3).  Multivariate  logistic  regression 
models were used to assess the diagnostic value of NT-proBNP, 
when  combined  with  clinical  parameters  (e.g.  systolic  blood 
p r e s s u r e  a n d  h e a r t  r a t e ) .  W e  f o u n d  t h a t  N T -  p r o B N P  a d d e d  
significant  diagnostic  information  to  the  clinical  parameters  when 
d i a g n o s i n g  c a r d i a c  t a mp o n a d e  ( F i g u r e  4 ) .
Intraobserver  and  interobserver  variability
The  mean  of  differences  between  two  measurements  made 
by the same examiner were 0.17±6.59 cm/s (from -9.2 to 16.8 
cm/s)  for  E,  -3.08±2.10  cm/s  (from  -4.8  to  0.20  cm/s)  for  A, 
-0.045±0.039 (from -0.06 to 0.03) for E/A ratio, -0.075±0.413 
cm/s (from -0.80 to 0.60 cm/s) for E', -0.666±1.129 (from -2.30 
to 0.86) for E/E' ratio, and -1.70±7.18 mL/m
2 (from -13.0 to 7.0 
mL/m
2)  for  LA  volume  index.  Interobserver  values  for  E,  A,  E/A 
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observers were in good agreement (r=0.960 for E, r=0.992 for A, 
r=0.983 for E/A ratio, r=0.964 for E', r=0.980 for E/E' ratio, and 
r=0.976  for  LA  volume  index).  However,  the  agreement  for  the 
D T  w a s  l e s s  r o b u s t  ( r = 0 . 5 9 7 ) ,  a n d  t h e  v a l u e  o f  t h i s  p a r a m e t e r  
was  excluded  from  the  analysis.
DISCUSSION
We  p e r f o r me d  a  c r o s s - s e c t i o n a l  s t u d y  t o  i n v e s t i ga t e  t h e  r o l e  
o f  N T - p r o B N P  i n  a s s e s s i n g  d i s e a s e  s e v e r i t y  i n  p a t i e n t s  w i t h  
p e r i c a r d i a l  e f f u s i o n s .  O u r  s t u d y  s h o w e d  t h a t  t h e  N T - p r o B N P  
serum  levels  were  increased  in  patients  with  jugular  venous 
distension, pulsus paradoxus, heart rate ≥100/min, exaggerated 
respiratory  variation  of  the  transmitral  inflow,  IVC  plethora,  and 
cardiac  tamponade.  The  NT-proBNP  levels  showed  positive 
correlation with the heart rate and IVC diameter. On ROC curve 
analysis, a  cut-off NT-proBNP  value  of 436  ng/L  showed  good 
specificity  and  sensitivity  in  diagnosing  cardiac  tamponade.  We 
also  found  that  NT-proBNP  added  significant  diagnostic 
information  to  the  clinical  parameters.
There are few reports concerning natriuretic peptide assay in 
pericardial effusion patients. In the study by Spodick et al,
19) the 
levels  of  atrial  natriuretic  peptide  did  not  increase  because  the 
compressed myocardium could not stretch. Recently, Fernandes 
et  al.
20) r e p o r t e d  t h a t  N T - p r o B N P  w a s  i n c r e a s e d  i n  p e r i c a r d i a l  
diseases and was associated with diastolic dysfunction. However, 
t hi s st udy di d not  show t he rel at i on bet ween NT- proBNP l evel s 
and  pericardial  effusion  severity.
Effect  of  compensatory  mechanisms
Patient  with  severe  pericardial  effusion  have  more  severely 
compromised  hemodynamics.  In  patients  suffering  from  critical 
tamponade,  cardiac  compensatory  mechanisms  such  as 
increased  heart  rate  principally  induced  by  beta-adrenergic 
activity,  peripheral  vasoconstriction,  increased  ejection  fraction, 
and  blood  volume  expansion  are  activated  to  maintain  cardiac 
o u t p u t  a n d  b l o o d  p r e s s u r e
2).  Any  additional  compensation 
provided by neurohormonal stimulation is similar to what occurs 
during  heart  failure
21).
In our study, NT-proBNP levels were related to the presence 
of  jugular  venous  distension  and  IVC  plethora.  Jugular  venous 
distension  and  IVC  plethora  result  from  compensatory 
vasoconstriction  and  fluid  retention  and  subsequently  increased 
blood  volume  and  venous  pressure  via  activation  of  the 
renin-angiotensin system
2, 3, 16). The NT-proBNP levels were also 
correlated  with  heart  rate,  which  increases  with  compensatory 
beta-adrenergic  stimulation.  Hanford  et  al.
22)  reported  that 
catecholamine infusion in rats is associated with increased BNP 
levels.  Furthermore,  angiotensin  II  effects  a  decrease  in  BNP 
degradation
23),  and  together  with  endothelin,  stimulates  BNP 
gene expression
24). Vinch et al.
25) suggested that the paradoxical 
increase in BNP levels seen after intravenous conscious sedation 
may be the result of counter-regulatory hormone release caused 
by  an  acute  decrease  in  blood  pressure.
Effect  of  hemodynamic  changes  and  reduced  coronary  flow
In  the  current  study,  NT-proBNP  levels  were  increased  in 
patients with pulsus paradoxus and with exaggerated respiratory 
variations  of  transmitral  inflow  related  to  increased  pericardial 
pressure  and  subsequent  accentuated  interdependence  of  the 
cardiac  chambers
2, 3, 26, 27).  In  those  patients  displaying  pulsus 
paradoxus  and  exaggerated  respiratory  change  of  transmitral 
inflow,  the  stroke  volume  and  cardiac  output  are  usually 
decreased,  and  this  leads  to  absolute  or  relative  hypotension. 
The  decrease  in  blood  pressure  may  induce  a  compensatory 
increase  in  counter-regulatory  hormones,  as  mentioned  above, 
and  reduce  coronary  flow.  It  is  well  known  that  elevated  BNP 
and NT-proBNP levels may be the result of cardiac ischemia via 
reduced coronary flow
28). However, although coronary blood flow 
is  reduced  in  tamponade,  there  is  no  ischemic  component 
because the coronary flow remains in proportion to the reduced 
work  of  the  heart
29).  Therefore,  reduced  coronary  flow  may  not 
be  the  main  impetus  behind  the  elevated  NT-proBNP  levels 
observed  in  the  present  study.
Effect  of  diastolic  function
Once the total intrapericardial volume has caused the pericar-
dium  to  reach  the  noncompliant  region  of  its  pressure-  volume 
relation,  even  small  increases  in  the  intrapericardial  volume 
sharply increase the intrapericardial pressure
1). Therefore, as the 
ventricles  begin  to  relax  at  the  end  of  systole,  they  are  initially 
constrained by the elevated intrapericardial pressure, resulting in 
a  pattern  of  parallel  upward  displacement  of  the  diastolic 
pressure-volume  curve
30).  Obtaining  only  echocardiographic 
evidence  of  increased  diastolic  filling  pressures  is  insufficient. 
Chamber  dimensions  obtained  in  a  single  echocardiography 
exam  cannot  accurately  predict  the  presence  or  severity  of 
cardiac  tamponade
1, 31).
In  the  current  study,  there  was  no  significant  correlation 
between  the  NT-proBNP  levels  and  either  the  LV  cavity 
dimensions or the LA volume index. One possible explanation for 
this  is  that,  although  the  diastolic  filling  pressures  were 
increased,  total  cardiac  volume  was  limited  by  the  pericardial 
effusion,  and  the  myocytes  could  not  stretch.  Hence,  the 
elevated  NT-proBNP  levels  in  the  study  patients  may  not  be 
related  to  chamber  dimensions.
In  the  current  study,  there  was  no  significant  correlation 
between the NT-proBNP levels and Doppler parameters, such as 
E  velocity,  A  velocity,  E/A  ratio,  E',  and  E/E'  ratio.  There  are Shin-Jae  Kim,  et  al  :  N-terminal  pro-B-type  natriuretic  peptide  in  pericardial  effusion 85
several reasons why the NT-proBNP levels were not related with 
the Doppler parameters of diastolic function. First, the E/E' ratios 
of many patients (49%) in our study ranged between 8 and 15, 
but only 8 patients (19%) had E/E' values > 15. The range of 8 
to 15 is considered to be a "gray zone" in the estimation of LV 
filling pressures, and therefore other parameters are required for 
an  accurate  prediction  of  filling  pressure
32, 33).  Second,  as 
m e n t i o n e d  i n  p r e v i o u s  s t u d i e s ,  B N P  s h o w e d  w e a k  c o r r e l a t i o n  
w i t h  L V  e n d - d i a s t o l i c  p r e s s u r e  a n d  l o w  s e n s i t i v i t y  f o r  t h e  
detection  of  elevated  LV  end-diastolic  pressure  in  patients  with 
normal  systolic  function
34).  Therefore,  we  believe  that  the  effect 
of compensatory mechanisms on the production of NT-proBNP, 
as mentioned above, was robust enough to mask the effect of 
d i a s t o l i c  d y s f u n c t i o n  o n  t h e  p r o d u c t i o n  o f  t h e  N T - p r o B N P  i n  
patients  with  pericardial  effusion.
Limitations  of  the  study
There are several limitations to this study. First, the number of 
patients in our study was small. Second, the patient group was 
h e t e r o g e n e o u s ;  t h e  e t i o l o g y  o f  p e r i c a r d i a l  e f f u s i o n  w a s  d i v e r s e , 
and  the  duration  of  pericardial  effusion  was  uncertain,  so  the 
influence  of  these  variables  on  NT-proBNP  levels  was  unclear. 
Third,  we  could  not  check  NT-proBNP  levels  after 
pericardiocentesis, so we lack comparison between NT-proBNP 
levels  before  and  after  pericardiocentesis.  Fourth,  our  study 
lacked invasive measurement of hemodynamics. There were also 
some  limitations  in  the  measurement  of  echocardiographic 
parameters  in  patients  with  unstable  hemodynamics.  In  the 
current  study,  the  interobserver  values  for  the  DT  from  two 
independent  observers  were  not  in  good  agreement  (r=0.597), 
perhaps  because  of  rapid  heart  rate  and  the  summation  of  E 
and  A  velocity,  especially  in  patients  with  cardiac  tamponade. 
H o w e v e r ,  i n t e r ob s e r v e r  v a l u e s  f o r  E ,  A ,  E / A  r a t i o ,  E ' ,  E / E '  r a tio 
and LA volume index were in good agreement. Therefore, we do 
not  believe  that  interobserver  variability  of  the  measurements 
affected  the  results  significantly.
Conclusion  and  clinical  implications
Abnormally elevated NT-proBNP levels are a special feature of 
patients  with  pericardial  effusions.  The  mechanism  behind  the 
increased NT-proBNP levels is not entirely clear, but NT-proBNP 
levels  may  be  the  result  of  counter-regulatory  hormone  release 
induced  by  compensatory  activation  of  the  adrenergic  and 
renin-angiotensin  systems.  However,  the  relation  between 
NT-proBNP levels and diastolic dysfunction could not be clearly 
assessed  and  would  be  of  interest  in  future  studies.
We believe that NT-proBNP measurement has potential as a 
simple, relatively cheap method for assessing disease severity in 
patients  with  pericardial  effusions.  Furthermore,  it  may  be  used 
in  the  diagnosis  of  cardiac  tamponade.  Our  findings  should  be 
further  assessed  in  prospective  studies  with  more  data  that 
could address the role of NT-proBNP in disease progression and 
more  precisely  determine  its  role  as  a  prognostic  marker  in 
patients  suffering  from  pericardial  effusion.
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